Last reviewed 2026-06-01 · How we verify

EBP11-F1

Entera Bio Ltd. · Phase 1 active Small molecule ✓ Verified Jun 2026

EBP11-F1 is a Small molecule drug developed by Entera Bio Ltd.. It is currently in Phase 1 development. Also known as: hPTH(1-34).

EBP11 is a small molecule being studied for its potential effects on conditions such as hypoparathyroidism, osteoporosis, fractures, and bone disease. It is being compared to EBP05 and Forteo 0.02 mg in a Phase 1b clinical trial to assess its safety and pharmacokinetics.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EBP11-F1
Also known as	hPTH(1-34)
Sponsor	Entera Bio Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EBP11-F1 CI brief — competitive landscape report
EBP11-F1 updates RSS · CI watch RSS
Entera Bio Ltd. portfolio CI

Frequently asked questions about EBP11-F1

What is EBP11-F1?

EBP11-F1 is a Small molecule drug developed by Entera Bio Ltd..

Who makes EBP11-F1?

EBP11-F1 is developed by Entera Bio Ltd. (see full Entera Bio Ltd. pipeline at /company/entera-bio-ltd).

Is EBP11-F1 also known as anything else?

EBP11-F1 is also known as hPTH(1-34).

What development phase is EBP11-F1 in?

EBP11-F1 is in Phase 1.

Manufacturer: Entera Bio Ltd. — full pipeline
Also known as: hPTH(1-34)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing